Child Sacrifice: The FDA Approved Remdesivir Based on a Trial in Which 3 out of 53 Children Died
The trial was conducted by Gilead, the developer of remdesivir, and there was no control group.
The mortality rate of children with no treatment against COVID is 0.005% (1 in 20,000 die).
Based on this trial, the mortality rate of children with remdesivir treatment is 5.66% (1 in 17.7 die).
Dr. Meryl Nass: “Over 70% had an adverse reaction, 21% had a serious adverse event, and three of the children died. Because there was no control group, it’s unclear how either Gilead or the FDA determined that the drug benefited children, because there’s nothing to compare it to.”
“You’ve got a dangerous drug that’s now going to be tested in babies, it’s fully approved but everyone who gets it is going to be a guinea pig because no proper studies are being done”
Gilead is at it again, Meryl Nass, M.D. likens FDA collaboration to approve dangerous drug Remdesivir for infants as young as 28 days old to Tamiflu in which Gilead ‘massaged’ data in order to get FDA approval.
“Approval was based on a single trial of 53 children conducted by Gilead”, 3 of which died, she unpacks.
Nass asserts that Remdesivir in general has been used improperly over the last 2 years during a period when the live virus is no longer present in the body.
WATCH FULL EPISODE CHD